Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
Richard CathomasSacha I RothschildStefanie HayozLukas BubendorfBerna C ÖzdemirBernhard KissAndreas ErdmannStefanie AeppliNicolas MachRäto T StrebelBoris HadaschikDominik BertholdHubert JohnDeborah ZihlerMathias SchmidIlaria AlborelliMartina SchneiderJana MusilovaMartin SpahnUlf PetrauschPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
The addition of perioperative durvalumab to the standard of care for patients with resectable MIUC results in a high EFS and OS at 2 years.